Friday 18 August 2023

Gene-Editing Cures HIV

A new gene-editing treatment called EBT-001 has been successfully tested in non-human primates to remove SIV, a virus related to HIV, from their genomes. This breakthrough research has led to the authorization of the first-ever clinical trial for an HIV gene-editing technology in humans by the FDA in 2022. EBT-101, the developed treatment, has shown promise in safely eliminating SIV from viral reservoirs in the primates' cells and tissues. The treatment was well-tolerated, and the results pave the way for potential HIV cures and other gene-editing therapies for infectious diseases. The ongoing clinical trial program is a significant step toward addressing HIV and related conditions.

No comments:

Post a Comment